JDRF and GNF Announce Innovative Diabetes Drug Discovery and Development Partnership
News Aug 06, 2009
The Juvenile Diabetes Research Foundation announces that it has entered into a novel collaborative research agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform.
"This agreement with GNF opens exciting new avenues for JDRF to speed the translation of basic research into drugs and treatments for type 1 diabetes," said Alan J. Lewis, PhD, President and Chief Executive Officer of JDRF.
"By creating this highly interactive collaboration with a world class organization with demonstrated expertise in discovering and developing innovative therapeutics for medical needs, we are looking to expand both the targets and the realm of possible treatments that can benefit people living with diabetes."
The partnership between JDRF and GNF aims to deliver a succession of drug candidates to the clinic over the next four years. The initial focus will be on pancreatic beta cell regeneration and survival, to restore beta cell function in diabetes. The program builds on current JDRF funding at GNF that has resulted in the discovery of beta cell regeneration drug targets and candidates, and allows for the inclusion of JDRF-funded projects and other discoveries into the program.
"Through this collaboration with JDRF, we are looking to create a unique program of translational research that fully exploits the strengths of each partner to produce a continuous source of novel insights, drug targets, and drug candidates," said Peter Schultz, PhD, Lead GNF Investigator and Institute Director.
Projects within the collaboration will be chosen and managed by a combined review committee of JDRF and GNF representatives, with oversight from a Scientific Advisory Board and JDRF volunteers.